|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-11-26
|
|
pubmed:abstractText |
Bortezomib is a proteasome inhibitor that has been approved by FDA for the treatment of multiple myeloma and that has completed phase 1 testing in children. The purpose of the current study was to evaluate the antitumor activity of bortezomib against the in vitro and in vivo childhood cancer preclinical models of the Pediatric Preclinical Testing Program (PPTP).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1545-5017
|
|
pubmed:author |
pubmed-author:CarolHernanH,
pubmed-author:HoughtonPeter JPJ,
pubmed-author:KeirStephen TST,
pubmed-author:KeshelavaNinoN,
pubmed-author:KolbE AndersEA,
pubmed-author:LockRichardR,
pubmed-author:MarisJohn MJM,
pubmed-author:MortonChristopher LCL,
pubmed-author:ReynoldsC PatrickCP,
pubmed-author:SmithMalcolm AMA,
pubmed-author:WuJianrongJ
|
|
pubmed:copyrightInfo |
(c) 2007 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
50
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
37-45
|
|
pubmed:dateRevised |
2009-1-12
|
|
pubmed:meshHeading |
pubmed-meshheading:17420992-Animals,
pubmed-meshheading:17420992-Antineoplastic Agents,
pubmed-meshheading:17420992-Boronic Acids,
pubmed-meshheading:17420992-Cell Line, Tumor,
pubmed-meshheading:17420992-Cell Proliferation,
pubmed-meshheading:17420992-Dose-Response Relationship, Drug,
pubmed-meshheading:17420992-Female,
pubmed-meshheading:17420992-Mice,
pubmed-meshheading:17420992-Mice, Inbred Strains,
pubmed-meshheading:17420992-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:17420992-Protease Inhibitors,
pubmed-meshheading:17420992-Pyrazines,
pubmed-meshheading:17420992-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
|
|
pubmed:affiliation |
St. Jude Children's Research Hospital, Memphis, Tennessee, USA. peter.houghton@stjude.org
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, N.I.H., Extramural
|
